Terms: = Breast cancer AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169 AND Clinical Outcome
11 results:
1. A concise review on the role of BDNF-AS in human disorders.
Ghafouri-Fard S; Khoshbakht T; Taheri M; Ghanbari M
Biomed Pharmacother; 2021 Oct; 142():112051. PubMed ID: 34426254
[TBL] [Abstract] [Full Text] [Related]
2. ezh2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy.
Bao Y; Oguz G; Lee WC; Lee PL; Ghosh K; Li J; Wang P; Lobie PE; Ehmsen S; Ditzel HJ; Wong A; Tan EY; Lee SC; Yu Q
Nat Commun; 2020 Nov; 11(1):5878. PubMed ID: 33208750
[TBL] [Abstract] [Full Text] [Related]
3. Methylation of ezh2 by PRMT1 regulates its stability and promotes breast cancer metastasis.
Li Z; Wang D; Lu J; Huang B; Wang Y; Dong M; Fan D; Li H; Gao Y; Hou P; Li M; Liu H; Pan ZQ; Zheng J; Bai J
Cell Death Differ; 2020 Dec; 27(12):3226-3242. PubMed ID: 32895488
[TBL] [Abstract] [Full Text] [Related]
4. Overview on Epigenetic Re-programming: A Potential Therapeutic Intervention in Triple Negative breast cancers.
Mohamad Hanif EA; Shah SA
Asian Pac J Cancer Prev; 2018 Dec; 19(12):3341-3351. PubMed ID: 30583339
[TBL] [Abstract] [Full Text] [Related]
5. Elevated expression of a pharmacologic Polycomb signature predicts poor prognosis in gastric and breast cancer.
Clermont PL; Fornaro L; Crea F
Epigenomics; 2017 Oct; 9(10):1329-1335. PubMed ID: 28875726
[TBL] [Abstract] [Full Text] [Related]
6. Multifaceted role of the polycomb-group gene ezh2 in hematological malignancies.
Sashida G; Iwama A
Int J Hematol; 2017 Jan; 105(1):23-30. PubMed ID: 27830540
[TBL] [Abstract] [Full Text] [Related]
7. NBAT1 suppresses breast cancer metastasis by regulating DKK1 via PRC2.
Hu P; Chu J; Wu Y; Sun L; Lv X; Zhu Y; Li J; Guo Q; Gong C; Liu B; Su S
Oncotarget; 2015 Oct; 6(32):32410-25. PubMed ID: 26378045
[TBL] [Abstract] [Full Text] [Related]
8. ezh2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells.
Mu Z; Li H; Fernandez SV; Alpaugh KR; Zhang R; Cristofanilli M
J Exp Clin Cancer Res; 2013 Sep; 32(1):70. PubMed ID: 24294976
[TBL] [Abstract] [Full Text] [Related]
9. Polycomb group protein ezh2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome.
Gong Y; Huo L; Liu P; Sneige N; Sun X; Ueno NT; Lucci A; Buchholz TA; Valero V; Cristofanilli M
Cancer; 2011 Dec; 117(24):5476-84. PubMed ID: 21713757
[TBL] [Abstract] [Full Text] [Related]
10. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers.
Wei Y; Xia W; Zhang Z; Liu J; Wang H; Adsay NV; Albarracin C; Yu D; Abbruzzese JL; Mills GB; Bast RC; Hortobagyi GN; Hung MC
Mol Carcinog; 2008 Sep; 47(9):701-6. PubMed ID: 18176935
[TBL] [Abstract] [Full Text] [Related]
11. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome.
Yu J; Yu J; Rhodes DR; Tomlins SA; Cao X; Chen G; Mehra R; Wang X; Ghosh D; Shah RB; Varambally S; Pienta KJ; Chinnaiyan AM
Cancer Res; 2007 Nov; 67(22):10657-63. PubMed ID: 18006806
[TBL] [Abstract] [Full Text] [Related]
